Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT107 in Chronic Hepatitis B
NCT01027065Phase 2Unknown
- Sponsor
- Cytheris SA
- Start
- Dec 2009
- Primary completion
- Nov 2012
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of recombinant human interleukin-7 in Chronic Hepatitis B (CHB) (3 arms), sponsored by Cytheris SA. Primary endpoint: Short and long-term safety and biological activity of CYT107 at Week 12. Status: unknown.
02
Drugs
recombinant human interleukin-7
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT01027065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01027065.